Azetukalner vs Opakalim
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Epilepsy
Shared mechanism: Kv7 potassium channel · full Epilepsy pipeline
Azetukalner
Developed by Xenon Pharmaceuticals
NCT05614063 · Phase 3 · completed
This was a randomized, double-blind, placebo-controlled Phase 3 trial in 380 adults with focal epilepsy. Both azetukalner doses produced a significantly greater reduction in monthly seizure frequency than placebo, 25 mg: -53.2% vs -10.4%; 15 mg: -34.5% vs -10.4%, meeting the trial primary comparison.
Caveat: this result is taken from a company announcement or a news report of one, not from the trial registry or a peer-reviewed publication. Treat the figures as the sponsor's own statement, not as independently verified evidence.
Next expected readout: April 2027 · NCT05667142 (registry estimate)
Reported efficacy
Median percent change (MPC) in monthly (28 days) focal seizure frequency from baseline to DBP for XEN1101 versus placebo. (From baseline through to the double blind period (week 12)): Median % reduction in monthly focal seizure frequency at Week 12 (X-TOLE2, double-blind period): 25 mg dose -53.2% vs placebo -10.4%; 15 mg dose -34.5% vs placebo -10.4% (met)
Result source: NCT05614063
Opakalim
Developed by Biohaven and partners
NCT06425159 · Phase 2/3 · terminated
This randomized, quadruple-masked Phase 2/3 study in idiopathic generalized epilepsy was terminated early by the sponsor after enrolling 27 participants. The company reports a longer time to second seizure with opakalim but no formal statistical test, so the result is unclear; a study stopped this far short of its plan is weak evidence.
Next expected readout: December 2026 · NCT06443463 (registry estimate)
Reported efficacy
Time to the Second Day with a Generalized Tonic Clonic (GTC) Seizure During the 24- week Double-blind Treatment Period (Baseline to Week 24 of Double-Blind Treatment Period): Closed early with 27 subjects: median time to second generalized tonic-clonic seizure 141 days with opakalim vs 47 days with placebo; no formal statistical test reported (Biohaven, 2026-05-26). (unclear)
Result source: NCT06425159
Results for Epilepsy
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | Azetukalner | Opakalim |
|---|---|---|
| Seizure frequency, % change | —Not posted · NCT05614063 | —Trial running · NCT06309966 |
| 50% responder rate | —Not posted · NCT05614063 | —Trial running · NCT06309966 |
| Seizure freedom | —Not posted · NCT05614063 | —Trial running · NCT06309966 |
Seizure frequency, % change
- Azetukalner
- —Not posted · NCT05614063
- Opakalim
- —Trial running · NCT06309966
50% responder rate
- Azetukalner
- —Not posted · NCT05614063
- Opakalim
- —Trial running · NCT06309966
Seizure freedom
- Azetukalner
- —Not posted · NCT05614063
- Opakalim
- —Trial running · NCT06309966
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
Reviewed results are available, but are not yet structured for this comparison. These sourced summaries are shown separately from the aligned rows.
Focal Onset Seizures
Shared mechanism: Kv7 potassium channel · full Focal Onset Seizures pipeline
Azetukalner
Developed by Xenon Pharmaceuticals
NCT05614063 · Phase 3 · completed
This was a randomized, double-blind, placebo-controlled Phase 3 trial in 380 adults with focal epilepsy. Both azetukalner doses produced a significantly greater reduction in monthly seizure frequency than placebo, 25 mg: -53.2% vs -10.4%; 15 mg: -34.5% vs -10.4%, meeting the trial primary comparison.
Caveat: this result is taken from a company announcement or a news report of one, not from the trial registry or a peer-reviewed publication. Treat the figures as the sponsor's own statement, not as independently verified evidence.
Next expected readout: January 2028 · NCT05716100 (registry estimate)
Reported efficacy
Median percent change (MPC) in monthly (28 days) focal seizure frequency from baseline to DBP for XEN1101 versus placebo. (From baseline through to the double blind period (week 12)): Median % reduction in monthly focal seizure frequency at Week 12 (X-TOLE2, double-blind period): 25 mg dose -53.2% vs placebo -10.4%; 15 mg dose -34.5% vs placebo -10.4% (met)
Result source: NCT05614063
Opakalim
Developed by Biohaven and partners
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
Next expected readout: December 2026 · NCT06443463 (registry estimate)
No aligned efficacy figure on record for this race.
Results for Focal Onset Seizures
There are not yet structured results for two selected drugs in this indication. Available results are listed below instead of an empty comparison table.
Opakalim: no structured comparison results are available for Focal Onset Seizures.
Reviewed results are available, but are not yet structured for this comparison. These sourced summaries are shown separately from the aligned rows.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Azetukalner's landscape · Opakalim's landscape